NexImmune, Inc.: Nasdaq/NYSE listing notice — NexImmune receives Nasdaq extension to Oct 23, 2023; stock moves to Capital Market

NexImmune, Inc.

Nasdaq granted 180-day extension until Oct 23, 2023 to regain $1 minimum bid price compliance.
Effective Apr 26, 2023, NexImmune common stock listing transferred to Nasdaq Capital Market.
Company may consider reverse stock split to regain compliance; risk of delisting remains.
Original non-compliance notice received Oct 25, 2022; grace period expired Apr 24, 2023.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

NexImmune, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

April 26, 2023, the listing of the Company’s Common Stock will be transferred to The Nasdaq Capital Market. The Company will continue to monitor the closing bid price of its Common Stock and may, if appropriate, consider implementing available options, including but not limited to, implementing a reverse stock split of its outstanding securities, to regain compliance with the Minimum Bid Price Requirement. If the Company does not regain compliance within the allotted compliance period, Nasdaq will provide notice that the Company’s Common Stock will be subject to delisting. The Company would th

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001193125-23-118539

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.